Of the many multicenteric clinical trials, MARINA (Minimally Classic/Occult Trial of Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD) were seminal trials of monthly ranibizumab (Lucentis; Genentech, San Francisco, CA, USA) therapy in eyes with minimally classic and occult nvAMD and predominantly classic nvAMD, respectively. Here, VEGFA is linked to choroidal neovascularization.